Global Immunoglobulin Market Report 2025 - 2031: Advancements in Immunotherapy & Competitive Landscape | CSL Limited, Takeda, Kamada Pharmaceuticals

The Global Immunoglobulin Market reached approximately US$16.24 billion in 2023 and is expected to grow to US$35.85 billion by 2032, representing a CAGR of 9.3% during the forecast period 2024-2032.

This growth comes from the increasing number of autoimmune and immunodeficiency disorders, improvements in immunoglobulin therapies, including subcutaneous and intravenous options, and broader clinical uses in neurology and hematology. North America leads the market, backed by strong healthcare infrastructure and high awareness. In contrast, Asia-Pacific is the fastest growing region because of rising diagnosis and treatment rates.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/immunoglobulin-market?ram

United States: Key Industry Developments

✅ October 2025: Otsuka Pharmaceutical released promising interim results for their Phase 3 VISIONARY study on sibeprenlimab for IgAN treatment, showing significant clinical benefits without safety compromise.

✅ September 2025: CSL Behring expanded plasma-collection and fractionation operations to meet growing demand, advancing their position as a global leader in immunoglobulin therapies.

✅ August 2025: Grifols invested in innovative subcutaneous immunoglobulin delivery technologies to improve patient convenience and adherence, enhancing market penetration in chronic immune deficiency treatments.

Japan: Key Industry Developments

✅ October 2025: Takeda Pharmaceutical Company advanced immunoglobulin research focusing on autoimmune and rare diseases, including development of novel formulations for enhanced efficacy and safety.

✅ September 2025: Japan increased healthcare funding to support immunoglobulin therapy accessibility, particularly for neurology and hematology applications.

✅ August 2025: Collaborative efforts between Japanese biotech firms and global players accelerated clinical trials and regulatory approvals of advanced immunoglobulin products to address rising immune disorder prevalence.

Mergers and Acquisitions (2025) - Immunoglobulin Market:

✅ CSL Limited - agreed to sell its Wuhan plasma and fractionation operations to Chengdu Rongsheng Pharmaceutical for $185 million, focusing on streamlined plasma supply and production efficiency.

✅ Lonza - completed $1.2 billion acquisition of Roche's Vacaville biologics facility, expanding bioreactor capacity by 330,000 liters to boost immunoglobulin manufacturing.

✅ Sanofi - acquired Dren Bio's DR-0201 bispecific myeloid engager for $1.9 billion, enhancing its immunology pipeline with innovative immune-reset therapies.

Key Players:

➡ Takeda Pharmaceuticals Inc. - Develops plasma-derived and specialty biopharmaceutical therapies.
➡ CSL Limited - Provides plasma protein biotherapies and influenza vaccines.
➡ Octapharma AG - Specializes in human protein products from human plasma and cell lines.
➡ Kedrion Biopharma Inc. - Manufactures and distributes plasma-derived therapies worldwide.
➡ Grifols, S.A. - Focuses on plasma medicines and diagnostic solutions.
➡ ADMA Biologics, Inc. - Produces specialty plasma-derived biologics for immune deficiencies.
➡ Pfizer Inc. - Offers biopharmaceutical products across immunology, oncology, and rare diseases.
➡ Kamada Pharmaceuticals - Develops plasma-derived and inhaled protein therapeutics.
➡ Cygnus Technologies - Provides analytical tools for biologics and biopharmaceutical testing.
➡ Emergent BioSolutions Canada Inc. - Delivers specialty products addressing public health threats.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=immunoglobulin-market?ram (Purchase 2 or more Repots and get 50% Discount)

Key Segments:

➥ By Type: Immunoglobulin G (IgG) (IgG1, IgG2, IgG3, IgG4), Immunoglobulin M (IgM), Immunoglobulin A (IgA) (IgA1, IgA2), Immunoglobulin D (IgD), Immunoglobulin E (IgE)
➥ By Form: Soluble Immunoglobulins, Membrane-Bound Immunoglobulins
➥ By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disorders, Myasthenia Gravis, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Others
➥ By Route of Administration: Intravenous, Subcutaneous, Others
➥ By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Research and Academic Centers, Others

Latest Industry News:

-CSL Behring and Takeda launched advanced subcutaneous immunoglobulin therapies in 2025, offering higher concentration and improved patient convenience through home-based infusions.

-Rising prevalence of immunodeficiency and autoimmune diseases, along with an aging population, is driving strong demand for immunoglobulin treatments worldwide.

-Innovations include antiviral immunoglobulins targeting emerging viral threats and recombinant antibody products enhancing safety and supply stability.

-Asia-Pacific shows fastest market growth due to better healthcare access and increased awareness, while North America remains the largest regional market.

Market Dynamics and Growth Drivers:

-Increasing prevalence of immune disorders and immunodeficiency diseases, such as primary and secondary immunodeficiencies, is driving the demand for immunoglobulin therapies.

-Ongoing advancements in immunotherapy, including innovative intravenous (IVIG) and subcutaneous (SCIG) immunoglobulin delivery methods, enhance treatment efficacy and patient compliance, promoting market growth.

-Rising awareness and diagnosis of autoimmune diseases and expanding applications of immunoglobulins in neurology, hematology, and infectious diseases contribute significantly to market expansion.

-Growing geriatric population and increasing healthcare infrastructure worldwide boost demand for immunoglobulin products as essential components in managing long-term, chronic immune-related conditions.

Research Process:

Both primary and secondary data sources have been used in the Global Immunoglobulin Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Speak to Our Analyst and get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/immunoglobulin-market?ram

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.